



## **Keizo Nakada to Join SanBio as Corporate Officer and Head of Production**

Tokyo, Japan and Mountain View Calif. – July 1, 2022 – The SanBio Group (SanBio Co., Ltd. and subsidiaries SanBio, Inc. and SanBio Asia Pte. Ltd.) hereby announces that Mr. Keizo Nakada joined the Group as a new Corporate Officer and Head of Production on July 1, 2022.

Previously, at Santen Pharmaceutical Co., Ltd., Mr. Nakada gained experience setting up overseas plants and serving as the head of a domestic plant. Afterward, as an executive officer and head of Product Supply Department, he established a stable global product supply system while successfully reducing costs. Later, as an executive officer in charge of production departments at Bushu Pharmaceuticals Ltd. and Taiko Pharmaceutical Co., Ltd., Mr. Nakada assumed responsibility for domestic production plants, supply chain management, quality control, and technological development. At the same time, he fully optimized the supply chains of these companies, achieving dramatic increases in production capacity.

In March 2022, the SanBio Group submitted an application to the Ministry of Health, Labour and Welfare (MHLW) for SB623, an investigational product being developed for patients suffering from chronic effects of traumatic brain injury (TBI). This application for manufacturing and marketing approval is the first that the SanBio Group has ever submitted to the MHLW. Under the leadership of Mr. Nakada, the SanBio Group will strengthen and optimize its domestic supply system for SB623 in the post-approval marketing process. At the same time, the Group will begin establishing a global supply system that will facilitate worldwide distribution of SB623.

Mr. Nakada commented as follows on joining the Company: "I am very pleased to join SanBio, which continues to make great strides in the field of regenerative medicine, and to be involved in the commercialization of SB623, which has the potential to become a new treatment for central nervous system disorders with high unmet medical needs, including chronic motor deficit caused by TBI. I will do my utmost to utilize the experience I have cultivated over many years in the pharmaceutical industry as we strive to stably bring new treatment methods to an ever-greater number of patients."

Keita Mori, CEO of the Company, commented as follows: "As we move forward with the commercialization of SB623, we are very pleased to welcome Mr. Nakada, who has built a remarkable track record related to the establishment of production systems and supply chains for pharmaceutical products in Japan and overseas. Under Mr. Nakada's leadership, we will continue to optimize our product supply system in Japan and abroad, as this system is crucial to fulfilling our vision of becoming a global leader in the field of regenerative medicine."

**About SanBio**

SanBio is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. SanBio targets patients with high unmet medical needs that cannot be addressed by existing medical treatments, mainly in diseases of the central nervous system. SanBio is headquartered in Tokyo, Japan and has subsidiaries based in Mountain View, California, and Singapore. Additional information about SanBio Group is available at <https://www.sanbio.com/en/>.

**For more information, contact:**

SanBio Co., Ltd.

Management Administration

Email: [info@sanbio.jp](mailto:info@sanbio.jp)